Skip to content
OpenCapital
Get started

USANA Health Sciences USNA Cash & Equivalents

Cash & Equivalents at other companies

Nature's Sunshine Products logo
Nature's Sunshine ProductsNATR
$87.58M+1.3%
Herbalife logo
HerbalifeHLF
$451.2M+37.0%
BellRing Brands logo
BellRing BrandsBRBR
$33.2M-24.9%
United Natural Foods logo
United Natural FoodsUNFI
$43M-17.3%
Natural Grocers by Vitamin Cottage logo
Natural Grocers by Vitamin CottageNGVC
$20.72M-2.3%
US Foods logo
US FoodsUSFD
$49M-51.5%

Other financials

Income statement

See full
Revenue$250.2M+0.3%
Gross profit$190.8M-3.2%
Operating income$13.9M-11.5%
Net income$7.5M-20.1%
EPS (diluted)$0.41-16.3%

Balance sheet

See full
Total debt$18.0M+10.8%
Total equity$543.6M+2.6%
Total assets$739.0M-1.0%

Cash flow

See full
Operating cash flow$9.8M-37.0%
CapEx$2.6M-5.6%
Free cash flow$7.1M-43.9%

Valuation

See full
Market cap$363.35M-36.1%
P/E18.1×+7.8×
P/S0.4×-0.3×

Profitability

See full
Gross margin77.6%-3.0pp
Operating margin3.8%-2.7pp
Net margin1.9%-4.4pp
FCF margin5.7%-1.1pp

Returns & leverage

See full
Return on equity3.2%-7.6pp
Debt / equity0×0.0×
Current ratio2.5×+0.5×

Where this comes from

Reported directly by USANA Health Sciences in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: USANA Health Sciences’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about USANA Health Sciences's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is USANA Health Sciences's cash & equivalents?
USANA Health Sciences (USNA) reported cash & equivalents of $165.66M in Q1 2026.
How has USANA Health Sciences's cash & equivalents changed year-over-year?
USANA Health Sciences's cash & equivalents decreased by 9.2% year-over-year, from $182.37M to $165.66M.
What is the long-term trend for USANA Health Sciences's cash & equivalents?
Over 5 years (2020 to 2025), USANA Health Sciences's cash & equivalents has grown at a -12.7% compound annual growth rate (CAGR), from $311.92M to $158.38M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.